Country: Ireland
Language: English
Source: HPRA (Health Products Regulatory Authority)
Phenylbutazone
Vetoquinol Ireland Limited
QM01AA01
Phenylbutazone
20 percent weight/volume
Solution for injection
POM: Prescription Only Medicine as defined in relevant national legislation
Dogs, Horses, Non food-producing horses
phenylbutazone
N.S.A.I.D.
Authorised
1989-10-01
Health Products Regulatory Authority 28 August 2019 CRN00987J Page 1 of 3 SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE VETERINARY MEDICINAL PRODUCT Phenylarthrite solution for injection 2 QUALITATIVE AND QUANTITATIVE COMPOSITION ACTIVE SUBSTANCE Phenylbutazone 20 % w/v EXCIPIENT Benzyl Alcohol 1 % w/v 3 PHARMACEUTICAL FORM Solution for injection. 4 CLINICAL PARTICULARS 4.1 TARGET SPECIES Dogs Horses declared as not being intended for slaughter for human consumption. 4.2 INDICATIONS FOR USE, SPECIFYING THE TARGET SPECIES For the treatment of arthritis, tendinitis, muscular and articular rheumatisms, congestive processes, hyperthermia, heatstroke, inflammatory complications of various traumatic or bacterial infections. (With approved antibiotic if necessary). 4.3 CONTRAINDICATIONS Do not use in treatment of animals suffering from cardiac, hepatic and renal deficiencies. Do not use in cats. Do not use in case of hypersensitivity to the active substance or to any of the excipients. Do not administer other non-steroidal anti-inflammatory drugs concurrently or within 24 hours of each other. 4.4 SPECIAL WARNINGS FOR EACH TARGET SPECIES The intravenous injections should be done slowly. In case of intravenous injection, avoid mixing blood and product in the syringe. Intramuscular injections should be done deeply in the muscular tissues. In all cases the injections should be performed under rigorous asepsis 4.5 SPECIAL PRECAUTIONS FOR USE SPECIAL PRECAUTIONS FOR USE IN ANIMALS Use in very young or old animals may involve additional risk. If such use cannot be avoided, animals require careful clinical management. Avoid use in any dehydrated, hypovolaemic or hypotensive animals as there is a potential risk of increased renal toxicity. Response to long term therapy should be monitored at regular intervals by a veterinary surgeon. SPECIAL PRECAUTIONS TO BE TAKEN BY THE PERSON ADMINISTERING THE VETERINARY MEDICINAL PRODUCT TO ANIMALS None. Health Products Regulatory Authority 28 August 2019 CRN00987J Page 2 of 3 4.6 ADVERSE Read the complete document